Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/22/2017 06/23/2017 06/26/2017 06/27/2017 06/28/2017 Date
83.96(c) 85.21(c) 82.92(c) 79.83(c) 79.97(c) Last
959 708 773 700 974 667 1 401 280 1 082 066 Volume
-0.66% +1.49% -2.69% -3.73% +0.18% Change
More quotes
Financials ($)
Sales 2017 76,4 M
EBIT 2017 -460 M
Net income 2017 -458 M
Finance 2017 390 M
Yield 2017 -
Sales 2018 144 M
EBIT 2018 -454 M
Net income 2018 -442 M
Finance 2018 372 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 90,7x
EV / Sales2018 48,2x
Capitalization 7 316 M
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics.It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined... 
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
06/26 ALNYLAM PHARMACEUTICALS : and Sanofi Genzyme to Present New Clinical Trial Resul..
06/26 ALNYLAM PHARMACEUTICALS : Reports New Positive Clinical Results for Givosiran (A..
06/22 ALNYLAM PHARMACEUTICALS : Significantly Expands Patent Portfolio with New Allowa..
06/19 ALNYLAM PHARMACEUTICALS : CEO, John Maraganore, Named BIO Chair for 2017-2018 Te..
06/12 ALNYLAM PHARMACEUTICALS : Significantly Expands Patent Portfolio with New Allowa..
06/09 ALNYLAM PHARMACEUTICALS : FDA Grants Breakthrough Therapy Designation for Alnyla..
06/07 ALNYLAM PHARMACEUTICALS : Expands Third Annual “Helping Hands” Commu..
06/06 ALNYLAM PHARMACEUTICALS, INC. : Regulation FD Disclosure (form 8-K)
06/01 ALNYLAM PHARMACEUTICALS : Prices Public Offering of Common Stock
06/01 ALNYLAM PHARMACEUTICALS : FDA Grants Breakthrough Therapy Designation For Alnyla..
More news
Sector news : Biotechnology & Medical Research - NEC
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
06/28Alnylam Pharmaceuticals, Inc. Expected to Post Q2 2017 Earnings of -$1.20 Per.. 
06/27New Clinical Results with Givosiran  
06/27TUESDAY TOP ANALYST UPGRADES & DOWNGRADES Pt. 2 $ALNY $AMN $ARNA $CAFD $.. 
06/27Alnylam Pharmaceuticals's PT raised by Credit Suisse Group to $96.00. outperf.. 
06/27Alnylam Pharmaceuticals's buy rating reiterated at Needham & Company LLC... 
More tweets
Qtime:23
News from SeekingAlpha
06/28 Unshakeable Alexion Sees Off Ra And Akari
06/27 New Clinical Results with Givosiran
06/26 Alnylam priced at perfection - JPMorgan; shares off 5%
06/26 Alnylam's givosiran shows treatment effect in early-stage hepatic porphyria s..
06/22 Premarket analyst action - healthcare
Advertisement
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEU...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 78,8 $
Spread / Average Target -1,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John M. Maraganore Chief Executive Officer & Director
Barry E. Greene President
Michael W. Bonney Chairman
Yvonne L. Greenstreet Chief Operating Officer & Executive Vice President
Manmeet Singh Soni Chief Financial Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICAL..113.60%7 316
INCYTE CORPORATION33.97%27 507
QUINTILES IMS HOLDINGS..19.12%19 551
LONZA GROUP27.12%16 118
CELLTRION, INC.--.--%12 272
ALKERMES PLC4.64%8 910
More Results